Research must provide ‘more good news on outcomes’ while patients need simple and effective information

On behalf of EHA, professor Giovanni Martinelli and professor Theo de Witte spoke of their cutting edge research and the next steps in personalized medicine research in hematology.

EHA Statement on COVID-19 Vaccines

EHA statement on coronavirus (COVID-19)

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

Shining a Light on Blood Cancer

EHA Launches Digital Campaign

In September 2021, the European Hematology Association (EHA) will honor Blood Cancer Awareness Month with an extensive digital campaign.

EHA statement on coronavirus (COVID-19)

The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).

Position of EHA on Clinical Trials

 

The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.

Position of EHA on Personalized Medicine

 

The challenge
Despite its apparent complexity, personalized medicine could transform healthcare, by tailoring healthcare solutions to the individual patient, delivering ‘the right treatment to the right patient at the right time’ – and helping to get more value from healthcare spending.…

Learn more on the EHA Campus

EHA has developed EHA Campus courses related to previous EHA-LSHBT Virtual Hematology Updates. The aim of the courses is to add to your learning experience, making the information discussed during the webinars available in an interactive and engaging way.